Liping Liu, HighTide Therapeutics founder and CEO
December 14, 2023 07:29 AM ESTUpdated 07:53 AM
Financing

Up­dat­ed: Meta­bol­ic drug de­vel­op­er High­T­ide Ther­a­peu­tics eyes $36M raise with HK IPO

Amber Tong

High­T­ide Ther­a­peu­tics, a biotech de­vel­op­ing drugs for meta­bol­ic and di­ges­tive dis­eases in both the US and Chi­na, is seek­ing to raise around $36 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times